Rheumatology (Oxford, England) · 2026
Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Yunjing, Guo Jianhui, Sun Jia, Wang Puyu, Feng Tienan, Fang Yuan, Chi Huihui, Sun Yue, Liu Honglei, Cheng Xiaobing, Ye Junna, Shi Hui, Zhou Zhuochao, Meng Jianfen, Hu Qiongyi, Jia Jinchao, Liu Tingting, Wang Mengyan, Yang Chengde, Jin Wei, Teng Jialin, Su Yutong
Аннотация
OBJECTIVES: The objective of this study was to compare the efficacy of adjunct plasma exchange (PE) therapy with standard therapy in idiopathic inflammatory myopathy (IIM) with anti-signal recognition particle (SRP) antibodies.
METHODS: Anti-SRP-positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan-Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors.
RESULTS: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03-0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22-19.12), P = 0.025] turned out to be independent predictors for long-term prognosis.
CONCLUSION: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.
METHODS: Anti-SRP-positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan-Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors.
RESULTS: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03-0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22-19.12), P = 0.025] turned out to be independent predictors for long-term prognosis.
CONCLUSION: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.